Moreadith Randall 4

What Happened

• Moreadith Randall, Chief Scientific Officer of Serina Therapeutics (SER), exercised options to acquire 4,000 shares (2,000 on 2026-01-20 and 2,000 on 2026-01-21) at $0.06 per share (total cost $240) and sold those 4,000 shares in open-market transactions (2,000 at $3.07 on 1/20 for $6,140; 2,000 at $3.00 on 1/21 for $6,000), generating gross proceeds of $12,140. The Form 4 also lists two derivative-conversion entries at $0.00 consideration (see Key Details).

Key Details

• Transaction dates and prices:
  • 2026-01-20: exercised 2,000 shares @ $0.06 (acquired), sold 2,000 @ $3.07 (disposed) — $6,140 proceeds
  • 2026-01-21: exercised 2,000 shares @ $0.06 (acquired), sold 2,000 @ $3.00 (disposed) — $6,000 proceeds
  • Two additional M-code derivative conversions shown at $0.00 consideration (listed as disposed)
• Total exercised/acquired: 4,000 shares at $0.06 ($240 total); total open-market sale proceeds: $12,140.
• Net proceeds before taxes/fees: approximately $11,900 (sale proceeds minus exercise cost).
• Shares owned after transaction: not disclosed in the provided filings summary.
• Footnote: F1 — the stock options were fully vested.
• Filing: Form 4 filed 2026-01-21 reporting 1/20–1/21 transactions; appears to be filed within typical SEC timing requirements.

Context

• This pattern (exercising options and immediately selling the resulting shares) is a common way for insiders to monetize vested options—often referred to as a cashless exercise and sale. It shows realization of gains but does not necessarily indicate a change in the insider’s view of the company’s prospects.
• Because the options were fully vested (F1), the exercises were permitted without additional vesting conditions. The extra derivative entries at $0.00 may reflect a conversion or settlement detail in the underlying award and do not change the cash proceeds reported from the open-market sales.